絞り込み

16398

広告

A Comparative Study of a New Class of Gastric Acid Suppressant Agent Named Vonoparazan versus Esomeprazole for the Eradication of Helicobacter pylori.

著者 Tsujimae M , Yamashita H , Hashimura H , Kano C , Shimoyama K , Kanamori A , Matsumoto K , Koizumi A , Momose K , Eguchi T , Fukuchi T , Fujita M , Okada A
Digestion.2016 Dec 29 ; 94(4):240-246.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (242view , 0users)

Full Text Sources

Medical

Miscellaneous

Helicobacter pylori eradication rates have decreased worldwide. Gastric acid inhibition during treatment is important to eradicate these bacteria successfully. A new potassium-competitive acid blocker, vonoprazan (VPZ), has been shown to achieve high eradication rates in a previous randomized controlled trial.
PMID: 28030862 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード